Abstract
We describe a case of severe reactivation of occult hepatitis B virus infection in a 49-year-old man, who was treated with high doses of chlorambucil for a Binet stage A B-cell chronic lymphocytic leukemia (B-CLL). The patient was initially treated with lamivudine and subsequently with lamivudine and adefovir dipivoxil combination therapy to control viral replication and allow for long-term anti-cancer chemotherapy with alemtuzumab (Campath-1H), which was introduced to rescue for a B-CLL relapse. During 20 months of anti-HBV therapy, ALT and HBV-DNA levels progressively declined and B-CLL was successfully kept under control by long-term alemtuzumab administration.
MeSH terms
-
Adenine / administration & dosage
-
Adenine / analogs & derivatives*
-
Adenine / therapeutic use
-
Alemtuzumab
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm / administration & dosage*
-
Antibodies, Neoplasm / therapeutic use
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / therapeutic use
-
Antiviral Agents / administration & dosage*
-
Antiviral Agents / therapeutic use
-
Drug Therapy, Combination
-
Hepatitis B / drug therapy*
-
Hepatitis B / virology
-
Humans
-
Lamivudine / administration & dosage*
-
Lamivudine / therapeutic use
-
Leukemia, Lymphocytic, Chronic, B-Cell / complications*
-
Organophosphonates / administration & dosage*
-
Organophosphonates / therapeutic use
-
Recurrence
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm
-
Antineoplastic Agents
-
Antiviral Agents
-
Organophosphonates
-
Lamivudine
-
Alemtuzumab
-
adefovir
-
Adenine